|
José B. Vázquez Tanus, MD
AFACC, FAARM, ABAARM FACA, CCRP
Board Certified Physician in Anti-Aging, Regenerative & Functional Medicine, Integrative Noninvasive Cardiology, Clinical Research, Internal Medicine. Certified Clinical Research Professional
CITYZENSHIP: USA - LANGUAGES: ENGLISH & SPANISH, FLUIDLY SPOKEN & WRITTE
|
MEDICAL & NON-MEDICAL EDUCATION.
1990 TO PRESENT: Private practice Non-Invasive Integrative Cardiology, Internal Medicine, Clinical Research, Anti Aging, Regenerative & Functional Medicine.
Sport Preventative and Nutritional Medicine.
Previous Invasive Experience: Approximately 2,500 R/L heart catheterizations, 600 permanent pacemaker’s implants.
Actual Non-Invasive experience: Over 10,000 echocardiograms, cardiac Doppler, Tissue Imaging Doppler, Trans-esophageal echoes, peripheral vascular ultrasounds with external carotid circulation. Vascular Scanning and Intima media thickness.
Ongoing experience, interpretation, and treatment modalities with Autonomic Nervous
System monitoring using The Non-Invasive Digital Measurement of The Autonomic Nervous System ANX 3.0; only monitor to assess Sympathovagal Balance using Deep Breathing, Valsalva maneuver and Postural Changes.
1990 to present, Clinical Research in a variety of clinical disciplines including Cardiovascular conditions, Diabetes Mellitus, Dyslipidemias, Pulmonary conditions, Hypertension, Osteoarthritis, Diabetic neuropathy.
Founder of Research & Cardiovascular Corporation.
1990 to present attendance of an investigator meeting for every clinical study included in this CV, these meetings always include description of the protocol, good clinical practice, patient protection, scientific background, regulatory compliance, and electronic data management with templates as T.A.O., Inform, and other data management, and commonly a verification test to issue a certificate.
2006-2008 Fellowship Training in Anti-Aging, Regenerative & Functional Medicine, including:
Participant competent to practice Anti-Aging and Regenerative Medicine without supervision in his or her area of medical specialty.
Participant involved in web broadcasts so that he or she will have ongoing feedback from experienced clinicians.
Extensive case studies will be included with each module.
Anti-Aging Medicine: Anti-aging medicine is a clinical/medical specialty and field of scientific research aimed at the early detection, prevention, treatment, and reversal of aged-related decline.
Regenerative Medicine: Regenerative Medicine optimizes the body’s endogenous mechanisms of self-repair and adds proven and near future exogenous treatments and technologies.
Functional Medicine: Functional Medicine is an integrative, science-based healthcare approach that treats illness and promotes wellness by focusing on the bio-chemically unique aspects of each patient, and then individually tailoring interventions to restore physiological, psychological, and structural balance.
Diplomate of The American Board of Anti-Aging, Regenerative and Functional Medicine.
Board Certified in Anti Aging Regenerative & Functional Medicine.
Board Certified in Integrative Medicine
Diplomate of College & Mind Body Medicine
Diplomate of Collage of Energy Medicine
2009 to 2010 Fellowship in Preventative Medicine Nutrition and Sport Medicine including 7 phases:
1989 to 1990 Third years Invasive, Interventional Non-Invasive Cardiology Damas- San Lucas Cardiovascular Program US accredited cardiovascular program.
1988-1989 Damas San Lucas Cardiovascular Fellowship Training Program with 6 months elective training San Juan Veterans Administration Cardiovascular Training Program Dr. Edgardo Hernandez, chief of Staff.
1987-1988 Damas San Lucas Cardiovascular Fellowship Training Program Chief of Staff Dr Felix M. Cortes, MACC FACP.
1986-1987 Damas Internal Medicine Residency Training Program.
1985-1986 Damas Internal Medicine Residency Training Program.
1985-1984 Damas Internal Medicine Residency Training Program.
1984-1983 Damas Hospital Transitional Year, rotation all specialties.
1983-1979 San Juan Bautista School of Medicine, Caguas Puerto Rico. US accredited medical school. Diploma, Doctor in Medicine.
1979-1973 University of Puerto Rico. Bachelor’s degree. Diploma. Major Concentration General Sciences. Minor Concentration Chemistry & Biology.
1973-1968 High School Our Lady of Pilar, Puerto Rico. Diploma.
Sport Preventative and Nutritional Medicine.
Previous Invasive Experience: Approximately 2,500 R/L heart catheterizations, 600 permanent pacemaker’s implants.
Actual Non-Invasive experience: Over 10,000 echocardiograms, cardiac Doppler, Tissue Imaging Doppler, Trans-esophageal echoes, peripheral vascular ultrasounds with external carotid circulation. Vascular Scanning and Intima media thickness.
Ongoing experience, interpretation, and treatment modalities with Autonomic Nervous
System monitoring using The Non-Invasive Digital Measurement of The Autonomic Nervous System ANX 3.0; only monitor to assess Sympathovagal Balance using Deep Breathing, Valsalva maneuver and Postural Changes.
1990 to present, Clinical Research in a variety of clinical disciplines including Cardiovascular conditions, Diabetes Mellitus, Dyslipidemias, Pulmonary conditions, Hypertension, Osteoarthritis, Diabetic neuropathy.
Founder of Research & Cardiovascular Corporation.
1990 to present attendance of an investigator meeting for every clinical study included in this CV, these meetings always include description of the protocol, good clinical practice, patient protection, scientific background, regulatory compliance, and electronic data management with templates as T.A.O., Inform, and other data management, and commonly a verification test to issue a certificate.
2006-2008 Fellowship Training in Anti-Aging, Regenerative & Functional Medicine, including:
- Module I: Anti-Aging Medicine, Bioidentical Hormonal Replacement Therapy and Thyroid Disease.
- Module II: Anti-Aging Medicine & Coronary Artery Disease.
- Module III: Anti-Aging Medicine: Gastroenterology, Neurology & Fatt acid metabolism.
- Module IV: Advance Nutrition and Detoxification.
- Module V: Clinical Incentives: Case studies in Anti-Aging Medicine and implementation of these treatment modalities into everyday practice.
- Module VI: Understanding the basics of homeopathy and learn how to formulate and write prescriptions for basic tinctures.
- Module VII: Advanced nutritional treatments and functional approach for Anti-Aging patients Anti-Aging and Regenerative Medicine.
Participant competent to practice Anti-Aging and Regenerative Medicine without supervision in his or her area of medical specialty.
Participant involved in web broadcasts so that he or she will have ongoing feedback from experienced clinicians.
Extensive case studies will be included with each module.
Anti-Aging Medicine: Anti-aging medicine is a clinical/medical specialty and field of scientific research aimed at the early detection, prevention, treatment, and reversal of aged-related decline.
Regenerative Medicine: Regenerative Medicine optimizes the body’s endogenous mechanisms of self-repair and adds proven and near future exogenous treatments and technologies.
Functional Medicine: Functional Medicine is an integrative, science-based healthcare approach that treats illness and promotes wellness by focusing on the bio-chemically unique aspects of each patient, and then individually tailoring interventions to restore physiological, psychological, and structural balance.
Diplomate of The American Board of Anti-Aging, Regenerative and Functional Medicine.
Board Certified in Anti Aging Regenerative & Functional Medicine.
Board Certified in Integrative Medicine
Diplomate of College & Mind Body Medicine
Diplomate of Collage of Energy Medicine
2009 to 2010 Fellowship in Preventative Medicine Nutrition and Sport Medicine including 7 phases:
- Patient Consult & Evaluation.
- Medical-Fitness Testing and Diagnosis
- Exerrcise-Sports Medicine Prescription.
- Program design.
- Exercise Sport Medicine Management.
- Nutriition Prescription.
1989 to 1990 Third years Invasive, Interventional Non-Invasive Cardiology Damas- San Lucas Cardiovascular Program US accredited cardiovascular program.
1988-1989 Damas San Lucas Cardiovascular Fellowship Training Program with 6 months elective training San Juan Veterans Administration Cardiovascular Training Program Dr. Edgardo Hernandez, chief of Staff.
1987-1988 Damas San Lucas Cardiovascular Fellowship Training Program Chief of Staff Dr Felix M. Cortes, MACC FACP.
1986-1987 Damas Internal Medicine Residency Training Program.
1985-1986 Damas Internal Medicine Residency Training Program.
1985-1984 Damas Internal Medicine Residency Training Program.
1984-1983 Damas Hospital Transitional Year, rotation all specialties.
1983-1979 San Juan Bautista School of Medicine, Caguas Puerto Rico. US accredited medical school. Diploma, Doctor in Medicine.
1979-1973 University of Puerto Rico. Bachelor’s degree. Diploma. Major Concentration General Sciences. Minor Concentration Chemistry & Biology.
1973-1968 High School Our Lady of Pilar, Puerto Rico. Diploma.
ORIGINAL PAPERS, PUBLICATIONS AS PRINCIPAL INVESTIGATOR OF RESEARCH & CARDIOVASCULAR CORPORATION AND ONGOING CLINICAL TRIALS
National Leader, Puerto Rico Region, for the VICTOR CLINICAL TRIAL
National Leader, Puerto Rico Region, for the VICTORIA CLINICAL TRIAL
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared with Oral Semaglutide in Adult Participants with Type 2 Diabetes ND Inadequate Glycemic Control with Metformin (ACHIEVE-3)
A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity (SURMOUNT-MMO)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT)
A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION @ PREVENT / V2P).
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults with Chronic Heart Failure With Reduced Ejection Fraction (VICTOR)
The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease (HORIZON).
A Phase 2 Study of Once-Daily LY3502970 Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities
Testosterone replacement therapy for assessment of long-term vascular events and efficacy response in hypogonadal men (TRAVERSE)
Protocol H9X-MC-GBGL Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients with Type 2 Diabetes Mellitus.
A multi-center, randomized, double blind parallel group dose finding study to assess the effect of 3 doses of LIK066 compared to placebo or empagliflozin in type 2 diabetes mellitus patients with heart failure.
A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel Study to Evaluate the Lipid Altering Efficacy Evaluate the Lipid-and Safety of L-410198 in Patients with Metabolic Syndrome and Dyslipidemia
An Extension to: A Multicenter, Double –Blind, Randomized, Placebo- and Active-Controlled, Parallel Study to Evaluate the Lipid-Altering Efficacy and Safety of L410198 in Patients with Metabolic Syndrome and Dyslipidemia to Determine the Lipid-Lowering Effects of L-410198 in Combination with Simvastatin
A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Glyburide Therapy in subjects with Type 2 Diabetes Who Have Glycemic Control on Sulfonylurea Therapy Alone.
A Phase 3, Randomized, Three-Arm, Double-Blind, Active Controlled, Parallel Group, Multicenter Trial to Evaluate the Safety and Efficacy of Muraglitazar in Combination with Metformin Compared to Glimepiride in Combination with Metformin in subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control n Metformin Therapy Alone.
An eight week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren/ valsartan / HCTZ (300/320/25mg), compared to the combinations of aliskerin / HCTZ (300/25mg) and valsartan / HCTZ (320/25mg) in patients with essential hypertension not adequately responsive to HCTZ 25 mg.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety Of Saxagliptin (BMS-477118) as Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control with Diet and Exercise.
A Multicenter, Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) In Combination with Thiazolidinedione Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone.
Protocol CV181039: A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and Metformin IR Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control.
A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety Of Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control.
A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol
Phosphate Modified Release Formulation (COREG-MR) with Metropolol Succine (Toprol XL) on the Lipid Profile in Normolidipidemic, or Mildly Dyslipidemic Hypertensive Patients.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to
Asses the Efficacy, Safety, and Tolerability of MK-0859 in Patients with Primary Hypercholesterolemia or Mixed Hyperlipidemia.
A Multi-center, randomized, open-label, active controlled, parallel arm study to compare the efficacy of 12 weeks of treatment with Vildagliptin 100 mg, qd to thiazolidinedione (TZD) as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy in a community-based practice setting.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0736 and MK-0916 in Hypertensive Patients
A 12-week, randomized, double blind, active-controlled, multi-centre, phase IIIB study comparing the efficacy and evaluating the safety of SYMBICORT pMDI 160/4.5 µg x 2 actuations twice daily versus budesonide HFA pMDI 160 µg x 2 actuations twice daily, in adult and adolescent (≥12 years) Hispanic subjects with asthma.
A Phase IIb, 12-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group dose-ranging study of GSK 189075 (dosed one and twice daily) in approximately 392 male and female subjects, aged 18 to 70 years with type 2 diabetes mellitus who are previously on maximum effective metformin monotherapy (≥1500mg per day)
A Multicenter, Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) In Combination with Thiazolidinedione Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone
A Phase 2, Prospective, Randomized, Double-blind, Placebo-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects who are Currently Being Treated with Renin-angiotensin System Inhibitors.
A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-week Study to Evaluate the
Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in
Elderly Patients with Hypercholesterolemia at Moderately High Risk for Coronary Heart Disease.
The PRIMO Study: Paricalcitol Capsules benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 3B/4
A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination with Metformin as Initial Therapy as Compared with Dapagliflozin Monotherapy and Metformin Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control.
A double-blind, dose-ranging, placebo-controlled, randomized study to evaluate the safety and efficacy of INCB013739 plus metformin compared to metformin alone on glycemic control in type 2 diabetic subjects not adequately controlled by metformin monotherapy.
A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of MK-0736 When Added to Ongoing Therapy with Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) in Patients with Diabetes and Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination with Thiazolidinedion Therapy in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone.
A 54 Week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300mg/ amlodipine 10 mg in patients with essential hypertension.
A 30 week, Multicenter, randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy in Dyslipidemic Subjects with Stage 3 chronic kidney disease.
A Multicenter, randomized, open label, active comparator-controlled study to assess theefficacy, safety and tolerability of taspoglutide (RO5073031) compared to exenatide in patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both.
A multi-center, randomized, open-label, active-controlled study to compare the efficacy, safety and tolerability of taspoglutide (RO5073031) versus insulin glargine in insulinnaïve type 2 diabetic patients inadequately controlled with metformin and sulphonylurea combination therapy.
The PRIMO Study: Paricalcitol Capsules benefics in Renal failure Induced cardiac Morbidity in subjects with Chronic Kidney Disease Stage 3B/4.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P-TIMI 50).
A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose Ranking Study to Evaluate the Efficacy, Safety, and Tolerability of MK-0736 When Added to Ongoing Therapy with Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) in Patients with Diabetes and Hypertension.
A multi-center, randomized, double-blind study to evaluate the efficacy and long-term afety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes.
Un Estudio Multicentrico, Aleatorizado, Doble Ciego, Controlado con Placebo para Evaluar los Eventos cardiovasculares Posteriores al Tratamiento con Alogliptina adicional al Cuidado Estandar en Pacientes con Diabtes Tipo 2 y Sindrome Coronario Agudo.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with Inadequately Controlled Hypertension treated with an Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotension Receptor Blocker (ARB) and an additional Antihypertensive Medication.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0736 and MK-0916 in Hypertensive Patients.
A Phase II, Open-Label, Dose Exposure Confirmation Study to Evaluate the Pharmacokinetics and Safety and Tolerability of Betrixaban (MK-4448) in Adult Patients with Non-Valvular Atrial Fibrillation or Atrial Flutter
RADAR: Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with AtRasentan – A Phase 2b, Prospective, Randomized, Double-Blind, PlaceboControlled Trial to Evaluate Safety and Efficacy.
Efficacy and safety of FIAsp Compared to insulin Aspart in combination with Insulin Gargline and Metformin in Adults with Type 2 Diabetes.
Phase 3 Multi-center double blind randomized placebo controlled parallel group evaluation pf the efiicacy and tolerability of PCSK9 enzyme in reducing the ocurrance of major cardiovascular events.
Phase 2 outpacient double blind, randomized parallel group, placebo-controlled, doseranging study of 3 different doses of PCSK9 Antibody.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P – TIMI 50).
A Randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP.
A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG-MR) with Metoprolol Succinate (Toprol-XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety ad Efficacy of Triple Therapy with Saxagliptin added to Dapagliflozin in Combination with Metformin compared to Therapy with Placebo added to Dapagliflozin in combination with Metformin in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin and Dapagliflozin.
An 8 week randomized, double-blind, parallel-group, multicenter, active-controlled dose escalation study to evaluate the efficacy and safety of aliskiren HCTZ (300/25 mg) compared to amlodipine (10 mg) in patients with stage 2 systolic hypertension and diabetes mellitus
26 weeks randomized, Double blind, active controlled study comparing the safety of Furoate Fomoterol MDI fixed dose combination versus Mometasone Furoate MDI monotherapy in adolescents and adults with persistent asthma
A multicenter randomized double blind parallel group, active controlled study to evaluate the efficacy and safety of both aliskiren monotherapy on morbidity and mortality in patients with chronic heart failure NYHA class II-IV
Canakinumab Anti-inflamatory Thrombosis Outcomes Study
Multicenter, randomized, double blind placebo controlled parallel group, Phase 2 B trial to evaluate the safety and efficacy BMS 823778 in Overweight and obese people.
Rosuvastatin to Prevent Events in Men and Women with Elevated C-Reactive Protein, published The New England Journal of Medicine November 20,2008 359;21.
Multicenter double blind clinical trial with Apixaban for stroke prevention in Atrial Fibrillation.
Cardiovascular Inflammation Reduction Trial
A Multicenter, Randomized, Double-Blind, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy ANS Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbility and Mortality in Patients with Chronic Heart Failure (NYHA CLASS II-IV). (PROTOCOL CSPP100F2301 NOVARTIS).
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxaglipin in Combination with Glyburide in Subjects with Type 2 Diabetes Who Have Inadequate Glymeric Control on Glycemic Control on Glyburide Alone.
A 26 Week Randomized, Double-Blinded, Active Cntrolled Study Comparing the Safety of Mometasome Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasome Furcate MDI Monotherapy in Adolescent and Adults with Persistent Asthma. (PROTOCOL NO. PO6241 ALSO KNOWN AS P202/MERCK).
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome (PROTOCOL SYR-322_402/TAKEDA).
A Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy and Safety of Dapaglipozin in Subjects with Type 2 Diabetes with Inadequately Controlled Hypertension on Angiotensin-Converting Enzyme Inhibitor (ACE) or Angiotensin Receptor Blocker (ARB) (PROTOCOL MB 102073/BMS) A Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy and Safety of Dapagliflozin in Subjects with Type 2 Diabetes with Inadecuately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor
Locker (ARB) and Additional Antihypertensive Medication (PROTOCOL MB 102077/BMS)
A Multicenter, Randomized, Double-Blind, Parallel Group, Phase 2B Trial to Evaluate the Safety and Efficacy and Safety of MS-823778 in Overweight and Obese Subjects with Inadequately Controlled Hypertension (PROTOCOL MB 121008/BMS)
Effects of Calcium Channel Blockers on Proteinuria in Patients with Diabetic Nephropathy. Journal of Clinical Hypertension Vol 10, No 10 October 2008.
The International Verapamil Tandolapril Study (INVEST). Randomized Clinical Trial Journal of The American Medical Association (JAMA) Vol 290, No 21, December 2003. University of Florida & ABBOTT pharmaceutical
Baseline Characteristics and Early Blood Pressure Control. The Convince Trial. Journal
Hypertension 2001, 37:12
Multicenter double blind placebo control study to evaluate efficacy of added therapy with a statin vs. statin therapy along in patients with hypercholesterolemia who have not reached A.T.P. III panel target LDL cholesterol level. Merck pharmaceutical.
Multicenter double blind, randomized placebo control 6-week study to evaluate the efficacy and safety of Ezetimibe Simvastatin combination tablet vs. Atorvastatin in patients with hypercholesterolemia. Vytorin. Merck Pharmaceutical.
Genetic Bio-markers study, sub study of The INVEST TRIAL.
Metabolic Syndrome and Dyslipidemias study, Merck pharmaceutical.
AVALON study. Multicenter randomized double blind placebo control, parallel group open label evaluation for the safety and efficacy of dual therapy with Atorvastatin plus Amlodipine when compared to either therapy alone in the treatment of patients with simultaneous hyperlipidemia and hypertension.
ACEON study. Multicenter six months trial, double blind, placebo control parallel group design to study the efficacy and safety of a daily oral dose of 125 mg Azimilide Hydrochloride for the prophylactic treatment of Atrial Fibrillation.
A.L.I.V.E. Study. Phase III (Azimilide post infarct survival evaluation) that examines the efficacy of Azimilide for the prevention of sudden death in high risk patients post myocardial infarct.
Isometric Exercise study Handgrip ten cases submitted to isometric exercise and addition Thallium 201 with coronary angiography. Original study.
Pulmonary Uptake Grading by Thallium 201 severity compared with coronary angiography of 2 & 3 vessel disease. Original study.
Permanent Pacemaker Infection. The Damas Hospital Experience. Presented at The Regional Meeting of The American College of Physician, San Juan Puerto Rico. Published at Journal Science – Ciencia. Fall 1988. Original study.
Echocardiography study of pericardial effusion with hemodynamic compromise signs. Retrospective study of admitted cases to Damas Hospital, with diastolic collapse. Presented at Third Puerto Rican Congress of Cardiology. Original study.
Sub lingual Captopril in Hypertensive Emergencies. Prospective clinical study conducted in Damas & Yauco area hospitals. Presented at Puerto Rican Congress of Cardiology April 1987. Published at Boletin de Asociacion Medica, June 1987. Original study.
Sublingual Nifedipine in Hypertensive Emergencies. Prospective Clinical study conducted in Damas & Yauco Area hospitals. Presented at Regional Meeting of The Puerto Rico Medical Association. Awarded by Perdue Frederick Awards fourth Place, Original Author and presenter.
Multicenter prospective randomized double blind placebo control, dose titration study of Nebivolol monotherapy in Hispanic patients with stage 2 hypertension. Forest Research Institute.
Glycemic effects of Nevibolol compared with Metoprolol extended release and compared with hydrochlorothiazide in hypertensive patients with type 2 Diabetes Mellitus. A pilot study. Forest Research Institute.
EMERGE trial Diabetic trial of Taspoglutide vs. insulin gargline in insulin naïve patients with type 2 Diabetic patients controlled with metformin. Roche pharmaceutical.
Paricalcitol Capsules benefits in Renal failure Induced cardiac Mortality in Subjects with Chronic Kidney Disease Stage 3B/4. Abbott.
Phase III double blind placebo controlled, randomized study to evaluate the efficacy of tested drug compared to metformin alone on Glycemic control in type 2 diabetic patients not adequately controlled with monotherapy. Incyte pharmaceuticals.
BMS protocol, randomized placebo controlled, active controlled, phase 3 of study drug in combination with Metformin as initial therapy as compared with study drug monotherapy and Metformin monotherapy in subjects with Type 2 Diabetes who have inadequate Glycemic control.
Multicenter Randomized Double blind placebo controlled Study to evaluate the safety and efficacy of study drug in addition to standard of care in patients with a history of atherosclerotic disease. Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events.
Novartis Hypertension Trial randomized double blind parallel design trial to evaluate the blood pressure lowering efficacy comparing moderate vs aggressive treatment regimen.
Novartis Hypertension trial randomized, double blind, parallel, multicenter active controlled dose escalation study with a Renin Blocker.
ABBOTT study with Zemplar on patient with Diabetic Neuropathy. Phase 2 Study.
ABBOTT study on Dyslipidemias, Renal impairment and Co-existence of Both.
ABBOTT clinical trial on Vitamin D deficiency, cardiac mortality and chronic kidney disease.
Clinical Trial on patients with Acute Coronary Syndrome. A Multicenter Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the safety & Efficacy of study drug in addition to standard of care with Thrombin receptor Antagonist.
Clinical Trial on Diabetes Mellitus in patients with Type 3 diabetes Mellitus. Phase 3 with Dapagliflozin in combination with Thiazolidinedione who have inadequate Glycemic control
Clinical Trial with Dipeptidyl peptidase IV (DPP-IV) enzyme Phase 3-b, 4-week multicenter, double blind, placebo-controlled vs. placebo as add on therapy to Metformin XR in patients with inadequate Glycemic control on diet and exercise and stable dose of Metformin XR> 1,500mg.
Multicenter, Randomized, Double-Blind, Parallel Arm, 12 Week Study to evaluate the Efficacy and Safety of Ezetimibe/Simvastatin in Elderly Patients with Hypercholesterolemia at Moderately High Risk and High Risk for Coronary Artery Disease.
Clinical Trial on Incretin Actions, Glucagon-Like Peptide 1 (GLP-1) effect of Dipeptidyl Peptidase IV in combination with metformin R in drug naïve patients with inadequate Glycemic control, phase 3 trial.
Anti-Thrombotic therapy in patients with Atrial Fibrillation compared with warfarin. Randomized, Double Blind Placebo Controlled Phase 3 trial.
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes – the ACCELERATE Study.
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes.
A Phase 2, outpatient, double-blind, randomized, parallel-group, placebo-controlled, dose-ranging study (3 dose levels Q4W and 2 dose levels Q8W), including up to an 8 week screening and run-in phase, a 16 week treatment phase, and an 8-week follow-up phase.
A randomized, 8-week, double-blind, parallel-group, active-controlled, multicenter study to evaluate the efficacy and safety of LCZ696 200 mg in comparison with olmesartan 20 mg in patiens with essential hypertension not adequately responsive to olmesartan 20 mg treatment.
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes – the ACCELERATE Study.
A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP.
Efficacy and safety of semaglutide once weekly insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes.
A Randomized, Placebo-Controlled, Double-Blinded, Parallel, Phase 2a Study to Evaluate the Safety and Efficacy of LY2623091 in Patients with Primary Hypertension.
Protocol l1V-MC-EIBH(a): The addition of evacetrapib to atorvastatin compared to placebo, high-intensity atorvastatin, and atorvastatin with ezetimibe to evaluate LDL-C lowering in patients with primary hyperlipidemia – the ACCENTUATE study
A 52 Week, Phase 3 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Eficacy, Safety and Torelability of PF-04950615 in Subjects with Primary Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation of the Efficacy, Safety, and Torelability of Bococizumab (PF-04950615), in Reducing the Ocurrence of Major Cardiovascular Events in High Risk Subjects
National Leader, Puerto Rico Region, for the VICTOR CLINICAL TRIAL
National Leader, Puerto Rico Region, for the VICTORIA CLINICAL TRIAL
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared with Oral Semaglutide in Adult Participants with Type 2 Diabetes ND Inadequate Glycemic Control with Metformin (ACHIEVE-3)
A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity (SURMOUNT-MMO)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT)
A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION @ PREVENT / V2P).
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults with Chronic Heart Failure With Reduced Ejection Fraction (VICTOR)
The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease (HORIZON).
A Phase 2 Study of Once-Daily LY3502970 Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities
Testosterone replacement therapy for assessment of long-term vascular events and efficacy response in hypogonadal men (TRAVERSE)
Protocol H9X-MC-GBGL Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients with Type 2 Diabetes Mellitus.
A multi-center, randomized, double blind parallel group dose finding study to assess the effect of 3 doses of LIK066 compared to placebo or empagliflozin in type 2 diabetes mellitus patients with heart failure.
A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel Study to Evaluate the Lipid Altering Efficacy Evaluate the Lipid-and Safety of L-410198 in Patients with Metabolic Syndrome and Dyslipidemia
An Extension to: A Multicenter, Double –Blind, Randomized, Placebo- and Active-Controlled, Parallel Study to Evaluate the Lipid-Altering Efficacy and Safety of L410198 in Patients with Metabolic Syndrome and Dyslipidemia to Determine the Lipid-Lowering Effects of L-410198 in Combination with Simvastatin
A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Glyburide Therapy in subjects with Type 2 Diabetes Who Have Glycemic Control on Sulfonylurea Therapy Alone.
A Phase 3, Randomized, Three-Arm, Double-Blind, Active Controlled, Parallel Group, Multicenter Trial to Evaluate the Safety and Efficacy of Muraglitazar in Combination with Metformin Compared to Glimepiride in Combination with Metformin in subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control n Metformin Therapy Alone.
An eight week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren/ valsartan / HCTZ (300/320/25mg), compared to the combinations of aliskerin / HCTZ (300/25mg) and valsartan / HCTZ (320/25mg) in patients with essential hypertension not adequately responsive to HCTZ 25 mg.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety Of Saxagliptin (BMS-477118) as Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control with Diet and Exercise.
A Multicenter, Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) In Combination with Thiazolidinedione Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone.
Protocol CV181039: A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and Metformin IR Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control.
A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety Of Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control.
A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol
Phosphate Modified Release Formulation (COREG-MR) with Metropolol Succine (Toprol XL) on the Lipid Profile in Normolidipidemic, or Mildly Dyslipidemic Hypertensive Patients.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to
Asses the Efficacy, Safety, and Tolerability of MK-0859 in Patients with Primary Hypercholesterolemia or Mixed Hyperlipidemia.
A Multi-center, randomized, open-label, active controlled, parallel arm study to compare the efficacy of 12 weeks of treatment with Vildagliptin 100 mg, qd to thiazolidinedione (TZD) as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy in a community-based practice setting.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0736 and MK-0916 in Hypertensive Patients
A 12-week, randomized, double blind, active-controlled, multi-centre, phase IIIB study comparing the efficacy and evaluating the safety of SYMBICORT pMDI 160/4.5 µg x 2 actuations twice daily versus budesonide HFA pMDI 160 µg x 2 actuations twice daily, in adult and adolescent (≥12 years) Hispanic subjects with asthma.
A Phase IIb, 12-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group dose-ranging study of GSK 189075 (dosed one and twice daily) in approximately 392 male and female subjects, aged 18 to 70 years with type 2 diabetes mellitus who are previously on maximum effective metformin monotherapy (≥1500mg per day)
A Multicenter, Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) In Combination with Thiazolidinedione Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone
A Phase 2, Prospective, Randomized, Double-blind, Placebo-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects who are Currently Being Treated with Renin-angiotensin System Inhibitors.
A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-week Study to Evaluate the
Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in
Elderly Patients with Hypercholesterolemia at Moderately High Risk for Coronary Heart Disease.
The PRIMO Study: Paricalcitol Capsules benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 3B/4
A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination with Metformin as Initial Therapy as Compared with Dapagliflozin Monotherapy and Metformin Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control.
A double-blind, dose-ranging, placebo-controlled, randomized study to evaluate the safety and efficacy of INCB013739 plus metformin compared to metformin alone on glycemic control in type 2 diabetic subjects not adequately controlled by metformin monotherapy.
A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of MK-0736 When Added to Ongoing Therapy with Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) in Patients with Diabetes and Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination with Thiazolidinedion Therapy in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone.
A 54 Week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300mg/ amlodipine 10 mg in patients with essential hypertension.
A 30 week, Multicenter, randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy in Dyslipidemic Subjects with Stage 3 chronic kidney disease.
A Multicenter, randomized, open label, active comparator-controlled study to assess theefficacy, safety and tolerability of taspoglutide (RO5073031) compared to exenatide in patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both.
A multi-center, randomized, open-label, active-controlled study to compare the efficacy, safety and tolerability of taspoglutide (RO5073031) versus insulin glargine in insulinnaïve type 2 diabetic patients inadequately controlled with metformin and sulphonylurea combination therapy.
The PRIMO Study: Paricalcitol Capsules benefics in Renal failure Induced cardiac Morbidity in subjects with Chronic Kidney Disease Stage 3B/4.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P-TIMI 50).
A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose Ranking Study to Evaluate the Efficacy, Safety, and Tolerability of MK-0736 When Added to Ongoing Therapy with Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) in Patients with Diabetes and Hypertension.
A multi-center, randomized, double-blind study to evaluate the efficacy and long-term afety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes.
Un Estudio Multicentrico, Aleatorizado, Doble Ciego, Controlado con Placebo para Evaluar los Eventos cardiovasculares Posteriores al Tratamiento con Alogliptina adicional al Cuidado Estandar en Pacientes con Diabtes Tipo 2 y Sindrome Coronario Agudo.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with Inadequately Controlled Hypertension treated with an Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotension Receptor Blocker (ARB) and an additional Antihypertensive Medication.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0736 and MK-0916 in Hypertensive Patients.
A Phase II, Open-Label, Dose Exposure Confirmation Study to Evaluate the Pharmacokinetics and Safety and Tolerability of Betrixaban (MK-4448) in Adult Patients with Non-Valvular Atrial Fibrillation or Atrial Flutter
RADAR: Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with AtRasentan – A Phase 2b, Prospective, Randomized, Double-Blind, PlaceboControlled Trial to Evaluate Safety and Efficacy.
Efficacy and safety of FIAsp Compared to insulin Aspart in combination with Insulin Gargline and Metformin in Adults with Type 2 Diabetes.
Phase 3 Multi-center double blind randomized placebo controlled parallel group evaluation pf the efiicacy and tolerability of PCSK9 enzyme in reducing the ocurrance of major cardiovascular events.
Phase 2 outpacient double blind, randomized parallel group, placebo-controlled, doseranging study of 3 different doses of PCSK9 Antibody.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P – TIMI 50).
A Randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP.
A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG-MR) with Metoprolol Succinate (Toprol-XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety ad Efficacy of Triple Therapy with Saxagliptin added to Dapagliflozin in Combination with Metformin compared to Therapy with Placebo added to Dapagliflozin in combination with Metformin in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin and Dapagliflozin.
An 8 week randomized, double-blind, parallel-group, multicenter, active-controlled dose escalation study to evaluate the efficacy and safety of aliskiren HCTZ (300/25 mg) compared to amlodipine (10 mg) in patients with stage 2 systolic hypertension and diabetes mellitus
26 weeks randomized, Double blind, active controlled study comparing the safety of Furoate Fomoterol MDI fixed dose combination versus Mometasone Furoate MDI monotherapy in adolescents and adults with persistent asthma
A multicenter randomized double blind parallel group, active controlled study to evaluate the efficacy and safety of both aliskiren monotherapy on morbidity and mortality in patients with chronic heart failure NYHA class II-IV
Canakinumab Anti-inflamatory Thrombosis Outcomes Study
Multicenter, randomized, double blind placebo controlled parallel group, Phase 2 B trial to evaluate the safety and efficacy BMS 823778 in Overweight and obese people.
Rosuvastatin to Prevent Events in Men and Women with Elevated C-Reactive Protein, published The New England Journal of Medicine November 20,2008 359;21.
Multicenter double blind clinical trial with Apixaban for stroke prevention in Atrial Fibrillation.
Cardiovascular Inflammation Reduction Trial
A Multicenter, Randomized, Double-Blind, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy ANS Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbility and Mortality in Patients with Chronic Heart Failure (NYHA CLASS II-IV). (PROTOCOL CSPP100F2301 NOVARTIS).
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxaglipin in Combination with Glyburide in Subjects with Type 2 Diabetes Who Have Inadequate Glymeric Control on Glycemic Control on Glyburide Alone.
A 26 Week Randomized, Double-Blinded, Active Cntrolled Study Comparing the Safety of Mometasome Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasome Furcate MDI Monotherapy in Adolescent and Adults with Persistent Asthma. (PROTOCOL NO. PO6241 ALSO KNOWN AS P202/MERCK).
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome (PROTOCOL SYR-322_402/TAKEDA).
A Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy and Safety of Dapaglipozin in Subjects with Type 2 Diabetes with Inadequately Controlled Hypertension on Angiotensin-Converting Enzyme Inhibitor (ACE) or Angiotensin Receptor Blocker (ARB) (PROTOCOL MB 102073/BMS) A Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy and Safety of Dapagliflozin in Subjects with Type 2 Diabetes with Inadecuately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor
Locker (ARB) and Additional Antihypertensive Medication (PROTOCOL MB 102077/BMS)
A Multicenter, Randomized, Double-Blind, Parallel Group, Phase 2B Trial to Evaluate the Safety and Efficacy and Safety of MS-823778 in Overweight and Obese Subjects with Inadequately Controlled Hypertension (PROTOCOL MB 121008/BMS)
Effects of Calcium Channel Blockers on Proteinuria in Patients with Diabetic Nephropathy. Journal of Clinical Hypertension Vol 10, No 10 October 2008.
The International Verapamil Tandolapril Study (INVEST). Randomized Clinical Trial Journal of The American Medical Association (JAMA) Vol 290, No 21, December 2003. University of Florida & ABBOTT pharmaceutical
Baseline Characteristics and Early Blood Pressure Control. The Convince Trial. Journal
Hypertension 2001, 37:12
Multicenter double blind placebo control study to evaluate efficacy of added therapy with a statin vs. statin therapy along in patients with hypercholesterolemia who have not reached A.T.P. III panel target LDL cholesterol level. Merck pharmaceutical.
Multicenter double blind, randomized placebo control 6-week study to evaluate the efficacy and safety of Ezetimibe Simvastatin combination tablet vs. Atorvastatin in patients with hypercholesterolemia. Vytorin. Merck Pharmaceutical.
Genetic Bio-markers study, sub study of The INVEST TRIAL.
Metabolic Syndrome and Dyslipidemias study, Merck pharmaceutical.
AVALON study. Multicenter randomized double blind placebo control, parallel group open label evaluation for the safety and efficacy of dual therapy with Atorvastatin plus Amlodipine when compared to either therapy alone in the treatment of patients with simultaneous hyperlipidemia and hypertension.
ACEON study. Multicenter six months trial, double blind, placebo control parallel group design to study the efficacy and safety of a daily oral dose of 125 mg Azimilide Hydrochloride for the prophylactic treatment of Atrial Fibrillation.
A.L.I.V.E. Study. Phase III (Azimilide post infarct survival evaluation) that examines the efficacy of Azimilide for the prevention of sudden death in high risk patients post myocardial infarct.
Isometric Exercise study Handgrip ten cases submitted to isometric exercise and addition Thallium 201 with coronary angiography. Original study.
Pulmonary Uptake Grading by Thallium 201 severity compared with coronary angiography of 2 & 3 vessel disease. Original study.
Permanent Pacemaker Infection. The Damas Hospital Experience. Presented at The Regional Meeting of The American College of Physician, San Juan Puerto Rico. Published at Journal Science – Ciencia. Fall 1988. Original study.
Echocardiography study of pericardial effusion with hemodynamic compromise signs. Retrospective study of admitted cases to Damas Hospital, with diastolic collapse. Presented at Third Puerto Rican Congress of Cardiology. Original study.
Sub lingual Captopril in Hypertensive Emergencies. Prospective clinical study conducted in Damas & Yauco area hospitals. Presented at Puerto Rican Congress of Cardiology April 1987. Published at Boletin de Asociacion Medica, June 1987. Original study.
Sublingual Nifedipine in Hypertensive Emergencies. Prospective Clinical study conducted in Damas & Yauco Area hospitals. Presented at Regional Meeting of The Puerto Rico Medical Association. Awarded by Perdue Frederick Awards fourth Place, Original Author and presenter.
Multicenter prospective randomized double blind placebo control, dose titration study of Nebivolol monotherapy in Hispanic patients with stage 2 hypertension. Forest Research Institute.
Glycemic effects of Nevibolol compared with Metoprolol extended release and compared with hydrochlorothiazide in hypertensive patients with type 2 Diabetes Mellitus. A pilot study. Forest Research Institute.
EMERGE trial Diabetic trial of Taspoglutide vs. insulin gargline in insulin naïve patients with type 2 Diabetic patients controlled with metformin. Roche pharmaceutical.
Paricalcitol Capsules benefits in Renal failure Induced cardiac Mortality in Subjects with Chronic Kidney Disease Stage 3B/4. Abbott.
Phase III double blind placebo controlled, randomized study to evaluate the efficacy of tested drug compared to metformin alone on Glycemic control in type 2 diabetic patients not adequately controlled with monotherapy. Incyte pharmaceuticals.
BMS protocol, randomized placebo controlled, active controlled, phase 3 of study drug in combination with Metformin as initial therapy as compared with study drug monotherapy and Metformin monotherapy in subjects with Type 2 Diabetes who have inadequate Glycemic control.
Multicenter Randomized Double blind placebo controlled Study to evaluate the safety and efficacy of study drug in addition to standard of care in patients with a history of atherosclerotic disease. Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events.
Novartis Hypertension Trial randomized double blind parallel design trial to evaluate the blood pressure lowering efficacy comparing moderate vs aggressive treatment regimen.
Novartis Hypertension trial randomized, double blind, parallel, multicenter active controlled dose escalation study with a Renin Blocker.
ABBOTT study with Zemplar on patient with Diabetic Neuropathy. Phase 2 Study.
ABBOTT study on Dyslipidemias, Renal impairment and Co-existence of Both.
ABBOTT clinical trial on Vitamin D deficiency, cardiac mortality and chronic kidney disease.
Clinical Trial on patients with Acute Coronary Syndrome. A Multicenter Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the safety & Efficacy of study drug in addition to standard of care with Thrombin receptor Antagonist.
Clinical Trial on Diabetes Mellitus in patients with Type 3 diabetes Mellitus. Phase 3 with Dapagliflozin in combination with Thiazolidinedione who have inadequate Glycemic control
Clinical Trial with Dipeptidyl peptidase IV (DPP-IV) enzyme Phase 3-b, 4-week multicenter, double blind, placebo-controlled vs. placebo as add on therapy to Metformin XR in patients with inadequate Glycemic control on diet and exercise and stable dose of Metformin XR> 1,500mg.
Multicenter, Randomized, Double-Blind, Parallel Arm, 12 Week Study to evaluate the Efficacy and Safety of Ezetimibe/Simvastatin in Elderly Patients with Hypercholesterolemia at Moderately High Risk and High Risk for Coronary Artery Disease.
Clinical Trial on Incretin Actions, Glucagon-Like Peptide 1 (GLP-1) effect of Dipeptidyl Peptidase IV in combination with metformin R in drug naïve patients with inadequate Glycemic control, phase 3 trial.
Anti-Thrombotic therapy in patients with Atrial Fibrillation compared with warfarin. Randomized, Double Blind Placebo Controlled Phase 3 trial.
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes – the ACCELERATE Study.
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes.
A Phase 2, outpatient, double-blind, randomized, parallel-group, placebo-controlled, dose-ranging study (3 dose levels Q4W and 2 dose levels Q8W), including up to an 8 week screening and run-in phase, a 16 week treatment phase, and an 8-week follow-up phase.
A randomized, 8-week, double-blind, parallel-group, active-controlled, multicenter study to evaluate the efficacy and safety of LCZ696 200 mg in comparison with olmesartan 20 mg in patiens with essential hypertension not adequately responsive to olmesartan 20 mg treatment.
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes – the ACCELERATE Study.
A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP.
Efficacy and safety of semaglutide once weekly insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes.
A Randomized, Placebo-Controlled, Double-Blinded, Parallel, Phase 2a Study to Evaluate the Safety and Efficacy of LY2623091 in Patients with Primary Hypertension.
Protocol l1V-MC-EIBH(a): The addition of evacetrapib to atorvastatin compared to placebo, high-intensity atorvastatin, and atorvastatin with ezetimibe to evaluate LDL-C lowering in patients with primary hyperlipidemia – the ACCENTUATE study
A 52 Week, Phase 3 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Eficacy, Safety and Torelability of PF-04950615 in Subjects with Primary Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation of the Efficacy, Safety, and Torelability of Bococizumab (PF-04950615), in Reducing the Ocurrence of Major Cardiovascular Events in High Risk Subjects
RESEARCH TRAINING & CERTIFICATIONS
Certified Clinical Research Professional by Society of Clinical Research Associates, certificate through 3/1/2012
National Leader for The VICTORIA Clinical Trial, VerICiguaT global study in subjects with Reduced ejection fraction (VICTORIA) from 2016 to end of trial, by MERCK Sharp & Dohme Corp.
Clinical Research Professional certification preparation Course February 6, 2009.
Training received at The American Academy of Pharmaceutical Physicians November 610, 2003.
Major national meetings attended and additional vascular training.
2018-2020 Experienced Advanced Cardiac Life Support.
2016-2018 Advanced Cardiac Life Support Certification
2002-2009 Advance & Basic Cardiac Life support provider
2004 Update & Recent Advances in Echocardiography, 30 hours of training with Mayo Clinic Staff.
2001-06 Introduction to vascular track, carotids and venous duplex Imaging. Arterial anatomy & Physiology Superficial Venous System, with proper scanning and techniques.
2001-04 Physician Interpretation vascular track 2, carotids, arterial & venous systems instrumentation and orientation, cerebrovascular anatomy & physiology Pulse wave & continuous wave and color flow Doppler with proper scanning procedures and protocols. Diagnostic investigative criteria
2001-04 Physician Interpretation track 3 carotids, arterial & venous. Overview of Normal and Abnormal Blood Flow and Anatomy, differentiating carotid artery plaque characteristics. Characterizing deep venous thrombosis. Reporting formats for venous and carotid duplex imaging
1998 Technicians and Physicians Workshop in Cardiac Ultrasound, Owen Brown symposium.
2003 and every other year attendance to American Heart Association National Meeting as well as American College of cardiology.
2000 ACRP clinical research coordination preparation course.
1998 Advanced heart Failure Tutorial with additional training at Ochsner Clinic New
Orleans
1997 Latest strategies future results managing hypertension & angina.
1996 Stress Echocardiography training.
1991 NASPE Preparation Course Atlanta, Georgia, Pacemaker implant training
1990 Symposium of Reperfusion Therapy, San Diego, California
1989 A new dimension of hypertension, the role of insulin resistance
1987 Pacing Seminar, Atlanta, Georgia
CERTIFICATES AND AWARDS
1997 Adult Echocardiography Certification as part of R.D.C.S.
April 1999 Invest: Elite Site Team.
March 2000 Invest: Recognition of Outstanding Invest Site Staff.
March 2009 Certified Clinical Research Professional.
January 2009 Diplomate American Board Anti-Aging, Regenerative and Functional Medicine.
LECTURES
Most important lectures, presented in local, national and international medical community.
HOSPITAL PRIVILEGES
Damas Hospital, Ponce PR active staff since 1989 to present in Internal Medicine & Cardiology, member at large Executive Committee for the period 1990 to 2000.
Damas Hospital Nuclear Cardiology Staff to present.
Dr Pila hospital, active staff from 1989 to 2006 in The department of Internal Medicine & Cardiology.
Chairman Internal Medicine Department for the period 2002 to 2006.
Founder and Co-director Non Invasive Cardiac Laboratory, Cardio-Dynamics Inc. based at Dr Pila Hospital
San Lucas Hospital, Ponce PR associate staff since 1993 to 2003 in Internal Medicine and Invasive cardiology.
Hospital Universitario, Ponce PR associate staff since 1997 to 1999 in Internal Medicine and Invasive & Non Invasive Cardiology.
APPOINTMENTS
Chairman, founder & medical director of Chest Pain Center Dr Pila Community Hospital
2001 to 2003
Chairman Internal medicine & Cardiology Department Dr Pila Community Hospital 2001-2003.
Member of the following committees Dr Pila Community Hospital: Intensive Care Unit.
Executive Committee
Diabetes Committee
Blood & Transfusions Committee
Infectious Committee
ASSOCIATIONS MEMBERSHIP
FELLOWSHIPS
2001 Fellow American College of Angiology
2001 Fellow American Society of Angiology
2009 Fellow of American Board Anti Aging Regenerative and Functional Medicine
2013 Fellow of American Association of Integrative Medicine
LICENSURES
1986-Present Unrestricted License
Puerto Rico Medical Board
November 6, 1986
NO. 7913
Department of Health of Puerto Rico
Internal Medicine Certification
Cardiology Certification
Unrestricted License of Michigan State
Florida State Medical License ACN840
1990 - 2009 Basic Course, License
04/17/2016-04/20/2018 ACLS provider by The American Heart Association
LEADERSHIP TRAINNING
Dale Carnegie Course certificate on leadership, Achieving Goals 12 week’s duration course.
Franklyn Covey FOCCUS Course.
HOBBIES
Physical Fitness, walking medicine.
Yoga
Classic Music
Golf
Painting
References and/or detailed number of invasive and non-invasive experiences, as well as described training of Anti- Aging Medicine, upon request.
Certified Clinical Research Professional by Society of Clinical Research Associates, certificate through 3/1/2012
National Leader for The VICTORIA Clinical Trial, VerICiguaT global study in subjects with Reduced ejection fraction (VICTORIA) from 2016 to end of trial, by MERCK Sharp & Dohme Corp.
Clinical Research Professional certification preparation Course February 6, 2009.
Training received at The American Academy of Pharmaceutical Physicians November 610, 2003.
- Key principles behind effective media
- How to handle actual media.
- How technology is changing the way medical information is converged to physician through CME.
- ACCME’S essential areas and their elements.
- Pharmaceutical research and manufacturers code on interactions with health care
- Role of world medical association and issues surrounding children’s health worldwide.
- FDA definitions of risk management
- Internet based technologies to accelerate drugs to market
- Risk management: Opportunities for investigation and where industry needs to go, Mexico & Japanese markets.
- Risk management assessment, two way chart including in it the two items of patient enrollment and quality conduct and data. The role of Latin American.
- Discuss preparing for an advisory committee meeting and experiences in the US drug review process.
- Discuss the process of building a phase 1 through phase IV research program in private and academic research centers.
- Review the development of new indications and intellectual property within a clinical research center.
- Career paths for clinical researchers and pharmaceutical investigators. 15-Duties as medical advisor in a global CRO 16Skills set required to succeed in industry.
Major national meetings attended and additional vascular training.
2018-2020 Experienced Advanced Cardiac Life Support.
2016-2018 Advanced Cardiac Life Support Certification
2002-2009 Advance & Basic Cardiac Life support provider
2004 Update & Recent Advances in Echocardiography, 30 hours of training with Mayo Clinic Staff.
- Simposio de la práctica de la ecocadiografia, actualizacion y presentacion de casos clinicos.
2001-06 Introduction to vascular track, carotids and venous duplex Imaging. Arterial anatomy & Physiology Superficial Venous System, with proper scanning and techniques.
2001-04 Physician Interpretation vascular track 2, carotids, arterial & venous systems instrumentation and orientation, cerebrovascular anatomy & physiology Pulse wave & continuous wave and color flow Doppler with proper scanning procedures and protocols. Diagnostic investigative criteria
2001-04 Physician Interpretation track 3 carotids, arterial & venous. Overview of Normal and Abnormal Blood Flow and Anatomy, differentiating carotid artery plaque characteristics. Characterizing deep venous thrombosis. Reporting formats for venous and carotid duplex imaging
- Vascular Screening for Cardiovascular Disease, including peripheral arterial, renal, carotids and abdominal aorta, with Gulfcoast Ultrasound Institute.
- Interpretation of the Complete Noninvasive Peripheral Vascular Examination &
- Advances in Cardiology
1998 Technicians and Physicians Workshop in Cardiac Ultrasound, Owen Brown symposium.
2003 and every other year attendance to American Heart Association National Meeting as well as American College of cardiology.
2000 ACRP clinical research coordination preparation course.
- Puerto Rico SBDC Estructura Legal de su negocio
- XXI st congress European Society of Cardiology
1998 Advanced heart Failure Tutorial with additional training at Ochsner Clinic New
Orleans
1997 Latest strategies future results managing hypertension & angina.
1996 Stress Echocardiography training.
1991 NASPE Preparation Course Atlanta, Georgia, Pacemaker implant training
1990 Symposium of Reperfusion Therapy, San Diego, California
1989 A new dimension of hypertension, the role of insulin resistance
1987 Pacing Seminar, Atlanta, Georgia
CERTIFICATES AND AWARDS
1997 Adult Echocardiography Certification as part of R.D.C.S.
April 1999 Invest: Elite Site Team.
March 2000 Invest: Recognition of Outstanding Invest Site Staff.
March 2009 Certified Clinical Research Professional.
January 2009 Diplomate American Board Anti-Aging, Regenerative and Functional Medicine.
LECTURES
Most important lectures, presented in local, national and international medical community.
- Risk reduction in heart disease.
- T-Channels in hypertension.
- Hyperlipidemia diagnoses and treatment.
- Hyperlipidemia and cardiovascular risk factors.
- Pericardial disease.
- Management of lipid disorder.
- Discussion & presentation AVERT study
- Non-Valvular Atrial fibrillation, thrombotic risk beyond the arrhythmia
- Diabetes management & pharmacologic therapy
- Altering clinical course of Heart Failure
- managing Hypertension & Angina
- Inflammation angiogenesis and ACE inhibition
- Cholesterol lowering in the patient with coronary heart disease
- Beyond symptom relieve, slowing the progression of heart failure.
- Platelets glycoprotein II-B/IIIA inhibitors new device
- The JNC IV discussion and presentation of Hypertension treatment
- Arterial wall; the new target for hypertension.
- Managing Lipids and risk reduction.
- Diabetes & the impact of risk factors clustering.
- Hypertension, rennin Blockers ACE receptor blockers.
- Member speaker Bureau Forest Pharmaceuticals for Bystolic
- Speaker for Eliquis
- Speaker for Zontivity
- Member Medical Board Vorapaxar
- Speaker at American Academy of Anti Aging Medicine Las Vegas International Conferences
- Speaker Stem Cells and Cardiovascular System
- Speaker Testosterone Replacement Therapy in The Cardiovascular Patient, International Conferences of Bio technology and Anti Aging Therapeutics.
HOSPITAL PRIVILEGES
Damas Hospital, Ponce PR active staff since 1989 to present in Internal Medicine & Cardiology, member at large Executive Committee for the period 1990 to 2000.
Damas Hospital Nuclear Cardiology Staff to present.
Dr Pila hospital, active staff from 1989 to 2006 in The department of Internal Medicine & Cardiology.
Chairman Internal Medicine Department for the period 2002 to 2006.
Founder and Co-director Non Invasive Cardiac Laboratory, Cardio-Dynamics Inc. based at Dr Pila Hospital
San Lucas Hospital, Ponce PR associate staff since 1993 to 2003 in Internal Medicine and Invasive cardiology.
Hospital Universitario, Ponce PR associate staff since 1997 to 1999 in Internal Medicine and Invasive & Non Invasive Cardiology.
APPOINTMENTS
Chairman, founder & medical director of Chest Pain Center Dr Pila Community Hospital
2001 to 2003
Chairman Internal medicine & Cardiology Department Dr Pila Community Hospital 2001-2003.
Member of the following committees Dr Pila Community Hospital: Intensive Care Unit.
Executive Committee
Diabetes Committee
Blood & Transfusions Committee
Infectious Committee
ASSOCIATIONS MEMBERSHIP
- American Academy of Physicians & Investigators 2003 to present.
- American Heart Association 1990 to present.
- American College of Cardiology 1990 to present.
- American Academy of Anti Aging Medicine 2004 to 2012 Council on Epidemiology & Prevention to present.
- Council on Atherosclerosis, thrombosis & Vascular Biology to present.
- Institute of Functional Medicine
- Member interdisciplinary group working group on quality of care and outcomes to present.
- Vascular Biology Working Group 2000 to present.
- Society of Clinical Research Associates.
- Fundación Puertorriqueña para la prevención de la Arterosclerosis 1993
- International Society of Cardiovascular Ultrasound 1993-1994
- American Society of Echocardiography 1989-2003
- American College of Physicians 1987-1995
- Medical Association of Puerto Rico 1979-1985
- Knights of Columbus 1979-1975
- Asociación Pro-Vida 1983-1984
- Asociación Puertorriqueña del Corazón 1983-1998
- Asociación Médica del Sur 1983-1985
FELLOWSHIPS
2001 Fellow American College of Angiology
2001 Fellow American Society of Angiology
2009 Fellow of American Board Anti Aging Regenerative and Functional Medicine
2013 Fellow of American Association of Integrative Medicine
- Fellow of the American Board for Certification in Homeland Security
- Fellow of Nutritional and Metabolic Medicine
- Fellow in Integrative Medicine by American Association of Integrative Medicine
LICENSURES
1986-Present Unrestricted License
Puerto Rico Medical Board
November 6, 1986
NO. 7913
Department of Health of Puerto Rico
Internal Medicine Certification
Cardiology Certification
Unrestricted License of Michigan State
Florida State Medical License ACN840
1990 - 2009 Basic Course, License
04/17/2016-04/20/2018 ACLS provider by The American Heart Association
LEADERSHIP TRAINNING
Dale Carnegie Course certificate on leadership, Achieving Goals 12 week’s duration course.
Franklyn Covey FOCCUS Course.
HOBBIES
Physical Fitness, walking medicine.
Yoga
Classic Music
Golf
Painting
References and/or detailed number of invasive and non-invasive experiences, as well as described training of Anti- Aging Medicine, upon request.
¡Each clinical trial is an opportunity to advance towards innovative solutions that enhance quality of life. With every discovery, we move closer to a healthier, more promising future. With every discovery, we move closer to a healthier, more promising future. Your participation not only drives science forward but is also a crucial step toward offering more effective and personalized treatments. Together, we're building a healthier future for all!
|
|
|